Adjuvant Global Health Technology Fund, L.P. 的 Form 4/A 修正申報
修正AN2 Therapeutics, Inc.（ANTX），2022/6/24 申報
- 申報編號
- 0000899243-22-024034
- 申報時間
- 2022/6/24 16:51 ET
- 交易日
- 2022/3/29
- 申報延遲
- 87 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/3/31
這份申報列了 5 筆非衍生性交易、4 筆衍生性交易。公開市場買進合計 $250.0 萬。交易後 87 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Adjuvant Global Health Technology Fund, L.P.CIK 0001783165 | 持股 10% 以上大股東 |
| Adjuvant Global Health Technology Fund DE, L.P.CIK 0001799812 | 持股 10% 以上大股東 |
| Adjuvant Capital Management, LLCCIK 0001935084 | 持股 10% 以上大股東 |
| Adjuvant Capital GP, L.P.CIK 0001935100 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/3/29 | Common Stock | C轉換處分 | −1,651,636 | $0.00 | $0 | 0 | 直接 | |
| 2022/3/29 | Common Stock | C轉換處分 | −312,415 | $0.00 | $0 | 0 | 間接 | |
| 2022/3/29 | Common Stock | C轉換處分 | −392,433 | $0.00 | $0 | 0 | 直接 | |
| 2022/3/29 | Common Stock | C轉換處分 | −74,230 | $0.00 | $0 | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
表 I 有 4 筆交易的價格引用這則附註。
- F2
Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
- F3
Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.